US6503480B1
(en)
|
1997-05-23 |
2003-01-07 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US6254854B1
(en)
|
1996-05-24 |
2001-07-03 |
The Penn Research Foundation |
Porous particles for deep lung delivery
|
US6433040B1
(en)
|
1997-09-29 |
2002-08-13 |
Inhale Therapeutic Systems, Inc. |
Stabilized bioactive preparations and methods of use
|
JP2001517692A
(ja)
*
|
1997-09-29 |
2001-10-09 |
インヘール セラピューティック システムズ, インコーポレイテッド |
ネブライザにおける使用のための安定化調製物
|
US6946117B1
(en)
*
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
GB9727102D0
(en)
*
|
1997-12-22 |
1998-02-25 |
Andaris Ltd |
Microparticles and their therapeutic use
|
KR100796220B1
(ko)
*
|
1998-06-29 |
2008-01-21 |
넥타르 테라퓨틱스 |
미립자 전달 시스템 및 사용 방법
|
WO2000000215A1
(en)
*
|
1998-06-29 |
2000-01-06 |
Inhale Therapeutic Systems, Inc. |
Particulate delivery systems and methods of use
|
US6630169B1
(en)
|
1999-03-31 |
2003-10-07 |
Nektar Therapeutics |
Particulate delivery systems and methods of use
|
US6223455B1
(en)
†
|
1999-05-03 |
2001-05-01 |
Acusphere, Inc. |
Spray drying apparatus and methods of use
|
ATE312601T1
(de)
*
|
1999-05-27 |
2005-12-15 |
Acusphere Inc |
Poröse arzneistoffmatrizen und deren herstellungsverfahren
|
JP4874483B2
(ja)
|
1999-06-09 |
2012-02-15 |
ロバート イー. シーバース |
超臨界流体補助ネブライゼーション及びバブル乾燥
|
US6858199B1
(en)
|
2000-06-09 |
2005-02-22 |
Advanced Inhalation Research, Inc. |
High efficient delivery of a large therapeutic mass aerosol
|
WO2001013891A2
(en)
*
|
1999-08-25 |
2001-03-01 |
Advanced Inhalation Research, Inc. |
Modulation of release from dry powder formulations
|
US6586008B1
(en)
|
1999-08-25 |
2003-07-01 |
Advanced Inhalation Research, Inc. |
Use of simple amino acids to form porous particles during spray drying
|
WO2001045731A1
(en)
|
1999-12-21 |
2001-06-28 |
Rxkinetix, Inc. |
Particulate drug-containing products and method of manufacture
|
US6761909B1
(en)
|
1999-12-21 |
2004-07-13 |
Rxkinetix, Inc. |
Particulate insulin-containing products and method of manufacture
|
DE60113388T2
(de)
|
2000-02-08 |
2006-06-14 |
3M Innovative Properties Co |
Verbesserte verfahren für kalten bildtransfer
|
GB0003935D0
(en)
*
|
2000-02-08 |
2000-04-12 |
King S College London |
Formulation for dry powder inhaler
|
AU4905701A
(en)
|
2000-02-08 |
2001-08-20 |
3M Innovative Properties Company |
Ink fixing materials and methods of fixing ink
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
AU6124601A
(en)
|
2000-05-10 |
2001-11-20 |
Alliance Pharmaceutical Corporation |
Phospholipid-based powders for drug delivery
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
AU2001254995A1
(en)
*
|
2000-05-15 |
2001-11-26 |
Vectura Limited |
Method of manufacturing particles
|
NZ523693A
(en)
*
|
2000-07-10 |
2004-08-27 |
Chiron Corp |
Macrolide formulations for inhalation and methods of treatment of endobronchial infections
|
US7141236B2
(en)
|
2000-07-28 |
2006-11-28 |
Nektar Therapeutics |
Methods and compositions for delivering macromolecules to or via the respiratory tract
|
DE10064219B9
(de)
*
|
2000-12-22 |
2009-02-12 |
Nasalis Pain Relief International Gmbh |
Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
|
US20030072717A1
(en)
|
2001-02-23 |
2003-04-17 |
Vapotronics, Inc. |
Inhalation device having an optimized air flow path
|
GB0106403D0
(en)
*
|
2001-03-15 |
2001-05-02 |
Pharmaceutical Profiles |
Labelling of dry powder formulations for inhalation
|
GB0107106D0
(en)
*
|
2001-03-21 |
2001-05-09 |
Boehringer Ingelheim Pharma |
Powder inhaler formulations
|
WO2002087542A1
(en)
*
|
2001-04-26 |
2002-11-07 |
Inhale Therapeutic Systems, Inc. |
Novel methods and compositions for delivering macromolecules to or via the respiratory tract
|
US7905230B2
(en)
|
2001-05-09 |
2011-03-15 |
Novartis Ag |
Metered dose inhaler with lockout
|
CA2448022C
(en)
*
|
2001-05-21 |
2013-11-12 |
Injet Digital Aerosols Limited |
Compositions for protein delivery via the pulmonary route
|
US6805853B2
(en)
|
2001-11-09 |
2004-10-19 |
Alexza Molecular Delivery Corporation |
Delivery of diazepam through an inhalation route
|
US6759029B2
(en)
|
2001-05-24 |
2004-07-06 |
Alexza Molecular Delivery Corporation |
Delivery of rizatriptan and zolmitriptan through an inhalation route
|
US20030051728A1
(en)
|
2001-06-05 |
2003-03-20 |
Lloyd Peter M. |
Method and device for delivering a physiologically active compound
|
EP1392258B1
(en)
|
2001-05-24 |
2008-11-26 |
Alexza Pharmaceuticals, Inc. |
Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
JP2005503425A
(ja)
|
2001-05-24 |
2005-02-03 |
アレックザ モレキュラー デリヴァリー コーポレイション |
所定の吸入ルートによる薬剤エステルの送出
|
US7540284B2
(en)
|
2001-06-20 |
2009-06-02 |
Novartis Pharma Ag |
Powder aerosolization apparatus and method
|
AU2002333644A1
(en)
|
2001-09-17 |
2003-04-01 |
Glaxo Group Limited |
Dry powder medicament formulations
|
EP1446104B2
(en)
|
2001-11-01 |
2011-08-03 |
Novartis AG |
Spray drying methods
|
AU2002363947A1
(en)
|
2001-11-21 |
2003-07-24 |
Alexza Molecular Delivery Corporation |
Delivery of caffeine through an inhalation route
|
JP2005514393A
(ja)
|
2001-12-19 |
2005-05-19 |
ネクター セラピューティクス |
アミノグリコシドの肺への供給
|
US8777011B2
(en)
|
2001-12-21 |
2014-07-15 |
Novartis Ag |
Capsule package with moisture barrier
|
WO2003077891A1
(fr)
*
|
2002-03-18 |
2003-09-25 |
Yamanouchi Pharmaceutical Co., Ltd. |
Compositions medicales en poudre pour inhalation et procede de production de celles-ci
|
US7008644B2
(en)
|
2002-03-20 |
2006-03-07 |
Advanced Inhalation Research, Inc. |
Method and apparatus for producing dry particles
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
US6941980B2
(en)
|
2002-06-27 |
2005-09-13 |
Nektar Therapeutics |
Apparatus and method for filling a receptacle with powder
|
AR040682A1
(es)
|
2002-07-25 |
2005-04-13 |
Pharmacia Corp |
Forma de dosificacion una vez al dia de pramipexol
|
WO2004030659A1
(en)
*
|
2002-09-30 |
2004-04-15 |
Acusphere, Inc. |
Sustained release porous microparticles for inhalation
|
US7516741B2
(en)
|
2002-12-06 |
2009-04-14 |
Novartis Ag |
Aerosolization apparatus with feedback mechanism
|
CA2509216A1
(en)
*
|
2002-12-13 |
2004-07-01 |
Adagit |
Pharmaceutical porous particles
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
US7669596B2
(en)
|
2002-12-31 |
2010-03-02 |
Novartis Pharma Ag |
Aerosolization apparatus with rotating capsule
|
TR200502522T2
(tr)
*
|
2002-12-31 |
2005-09-21 |
Nektar Therapeutics |
Çözünmez bir aktif madde içeren farmasötik formülasyon
|
WO2004073729A1
(ja)
|
2003-02-21 |
2004-09-02 |
Translational Research Ltd. |
薬物の経鼻投与用組成物
|
WO2004075913A1
(ja)
|
2003-02-28 |
2004-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
タンパク質含有安定化製剤
|
AU2003220808B2
(en)
|
2003-03-27 |
2008-08-21 |
Bioactis Limited |
Powder medicine applicator for nasal cavity
|
PL1610850T3
(pl)
|
2003-04-09 |
2012-11-30 |
Novartis Ag |
Urządzenie rozpylające z osłoną wlotu powietrza
|
CA2520265C
(en)
|
2003-04-09 |
2015-02-17 |
Nektar Therapeutics |
Aerosolization apparatus with capsule puncture alignment guide
|
US8869794B1
(en)
|
2003-04-09 |
2014-10-28 |
Novartis Pharma Ag |
Aerosolization apparatus with capsule puncturing member
|
WO2004104490A1
(en)
|
2003-05-21 |
2004-12-02 |
Alexza Pharmaceuticals, Inc. |
Self-contained heating unit and drug-supply unit employing same
|
US7862834B2
(en)
|
2003-05-28 |
2011-01-04 |
Novartis Pharma Ag |
Pharmaceutical formulation comprising a water-insoluble active agent
|
CA2533887A1
(en)
*
|
2003-09-30 |
2005-04-14 |
Acusphere, Inc. |
Injectable, oral, or topical sustained release pharmaceutical formulations
|
US7621299B2
(en)
|
2003-10-03 |
2009-11-24 |
Cabot Corporation |
Method and apparatus for filling a vessel with particulate matter
|
EP1677738A2
(en)
*
|
2003-10-31 |
2006-07-12 |
Point Biomedical Corporation |
Reconstitutable microsphere compositions useful as ultrasonic contrast agents
|
EP1701714A2
(en)
|
2004-01-07 |
2006-09-20 |
Nektar Therapeutics |
Improved sustained release compositions for pulmonary administration of insulin
|
AU2005232441B2
(en)
*
|
2004-04-13 |
2010-11-11 |
Cambridge Biostability Limited |
Liquids containing suspended glass particles
|
ITMI20040795A1
(it)
*
|
2004-04-23 |
2004-07-23 |
Eratech S R L |
Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
|
US8012457B2
(en)
|
2004-06-04 |
2011-09-06 |
Acusphere, Inc. |
Ultrasound contrast agent dosage formulation
|
WO2006002140A2
(en)
|
2004-06-21 |
2006-01-05 |
Nektar Therapeutics |
Compositions comprising amphotericin b
|
US8513204B2
(en)
|
2004-06-21 |
2013-08-20 |
Novartis Ag |
Compositions comprising amphotericin B, mehods and systems
|
US8673360B2
(en)
|
2004-08-10 |
2014-03-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Compositions that enable rapid-acting and highly absorptive intranasal administration
|
JP4785847B2
(ja)
|
2004-08-13 |
2011-10-05 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
|
BRPI0513848A
(pt)
|
2004-08-13 |
2008-05-20 |
Boehringer Ingelheim Int |
formulação de pélete de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável deste, método para fabricação da mesma e uso desta
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
KR20070121786A
(ko)
|
2005-03-23 |
2007-12-27 |
엘란 파마 인터내셔널 리미티드 |
나노입자형 코르티코스테로이드 및 항히스타민 제제
|
JO3058B1
(ar)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
|
WO2006124446A2
(en)
*
|
2005-05-12 |
2006-11-23 |
Nektar Therapeutics |
Sustained release microparticles for pulmonary delivery
|
EP1893273B1
(en)
|
2005-05-18 |
2014-06-25 |
Nektar Therapeutics |
Adapter for use with aerosolization device for endobronchial therapy
|
PE20061444A1
(es)
|
2005-05-19 |
2007-01-15 |
Centocor Inc |
Anticuerpo anti-mcp-1, composiciones, metodos y usos
|
JP2009501006A
(ja)
|
2005-06-30 |
2009-01-15 |
セントカー・インコーポレーテツド |
抗il−23抗体、組成物、方法および用途
|
ITMI20051999A1
(it)
|
2005-10-21 |
2007-04-22 |
Eratech S R L |
Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
|
JP5113328B2
(ja)
*
|
2005-11-07 |
2013-01-09 |
田辺三菱製薬株式会社 |
エマルション並びにそれを用いた目的物質粒子の製造方法及び医薬品
|
US8293869B2
(en)
|
2005-12-16 |
2012-10-23 |
Nektar Therapeutics |
Polymer conjugates of GLP-1
|
HUE034269T2
(en)
|
2005-12-29 |
2018-02-28 |
Janssen Biotech Inc |
Human anti-IL-23 antibodies, preparations, methods and applications
|
US20100226990A1
(en)
*
|
2006-01-27 |
2010-09-09 |
The Provost, Fellows And Scholars Of The College O |
Method of Producing Porous Microparticles
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
KR101200728B1
(ko)
|
2006-08-09 |
2012-11-13 |
인타르시아 세라퓨틱스 인코포레이티드 |
삼투성 전달 시스템 및 피스톤 조립체
|
ES2652415T3
(es)
|
2006-12-26 |
2018-02-02 |
Shin Nippon Biomedical Laboratories, Ltd. |
Preparación para aplicación transnasal
|
EP2121088B1
(en)
|
2007-03-09 |
2016-07-13 |
Alexza Pharmaceuticals, Inc. |
Heating unit for use in a drug delivery device
|
AU2008244523B2
(en)
|
2007-04-23 |
2012-02-16 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
WO2009023803A2
(en)
*
|
2007-08-15 |
2009-02-19 |
Abbott Respiratory Llc |
Modulated release formulation for the delivery of one or more medicaments
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
WO2009120619A2
(en)
*
|
2008-03-24 |
2009-10-01 |
Novartis Ag |
Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
|
PL220269B1
(pl)
|
2008-04-21 |
2015-09-30 |
Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna |
Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
|
US8834930B2
(en)
|
2008-05-15 |
2014-09-16 |
Novartis Ag |
Pulmonary delivery of a fluoroquinolone
|
EP2350118B1
(en)
|
2008-09-19 |
2016-03-30 |
Nektar Therapeutics |
Carbohydrate-based drug delivery polymers and conjugates thereof
|
CA2741834C
(en)
|
2008-10-31 |
2022-04-05 |
Centocor Ortho Biotech Inc. |
Fibronectin type iii domain based scaffold compositions, methods and uses
|
MX2011004730A
(es)
*
|
2008-11-04 |
2011-05-30 |
Cipla Ltd |
Composicion farmaceutica en aerosol.
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
EP2396011B1
(en)
|
2009-02-12 |
2016-04-13 |
Janssen Biotech, Inc. |
Fibronectin type iii domain based scaffold compositions, methods and uses
|
EP2221048A1
(en)
|
2009-02-18 |
2010-08-25 |
Siegfried Generics International AG |
Pharmaceutical composition for inhalation
|
DK2413902T3
(da)
|
2009-03-18 |
2019-10-07 |
Incarda Therapeutics Inc |
Enhedsdoser, aerosoler, kits og fremgangsmåder til behandling af hjertetilstande ved pulmonal indgivelse
|
JP5671001B2
(ja)
|
2009-03-26 |
2015-02-18 |
パルマトリックス,インコーポレイテッド |
肺疾患を治療するための乾燥粉末製剤および方法
|
GB0908129D0
(en)
*
|
2009-05-12 |
2009-06-24 |
Innovata Ltd |
Composition
|
KR20100123240A
(ko)
*
|
2009-05-15 |
2010-11-24 |
포항공과대학교 산학협력단 |
호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
|
WO2010131486A1
(en)
|
2009-05-15 |
2010-11-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Intranasal pharmaceutical compositions with improved pharmacokinetics
|
CN107412212B
(zh)
*
|
2009-05-29 |
2021-01-22 |
珍珠治疗公司 |
经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统
|
US8815258B2
(en)
|
2009-05-29 |
2014-08-26 |
Pearl Therapeutics, Inc. |
Compositions, methods and systems for respiratory delivery of two or more active agents
|
GB2472327B
(en)
|
2009-07-31 |
2013-03-13 |
Shin Nippon Biomedical Lab Ltd |
Intranasal granisetron and nasal applicator
|
SI2462246T1
(en)
|
2009-09-28 |
2018-01-31 |
Intarcia Therapeutics, Inc. |
Fast-setting and / or cessation of substantially unchanged delivery of the product
|
CN102811715A
(zh)
*
|
2009-12-08 |
2012-12-05 |
悉尼大学 |
可吸入制剂
|
EP2611438B1
(en)
|
2010-08-30 |
2020-04-01 |
Pulmatrix Operating Company, Inc. |
Dry powder formulations and methods for treating pulmonary diseases
|
EP2448571B1
(en)
|
2010-08-30 |
2013-06-12 |
Pulmatrix, Inc. |
Respirably dry powder comprising calcium lactate, sodium chloride and leucine
|
MX354828B
(es)
|
2010-09-29 |
2018-03-22 |
Pulmatrix Operating Co Inc |
Polvos secos de cationes metálicos monovalentes para inhalación.
|
DK3470057T3
(da)
|
2010-09-29 |
2021-11-22 |
Pulmatrix Operating Co Inc |
Kationiske tørpulvere omfattende magnesiumsalt
|
CA2816119C
(en)
*
|
2010-10-29 |
2019-03-05 |
Western University Of Health Sciences |
Ternary mixture formulations
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
JP2014510064A
(ja)
*
|
2011-02-25 |
2014-04-24 |
ザ ジョンズ ホプキンス ユニバーシティ |
Nrf2活性剤としてのカルコン誘導体
|
GB201108039D0
(en)
|
2011-05-13 |
2011-06-29 |
Mexichem Amanco Holding Sa |
Compositions
|
SG194896A1
(en)
*
|
2011-05-17 |
2013-12-30 |
Pearl Therapeutics Inc |
Compositions, methods & systems for respiratory delivery of two or more active agents
|
GB201117621D0
(en)
*
|
2011-10-12 |
2011-11-23 |
Mexichem Amanco Holding Sa |
Compositions
|
GB201117619D0
(en)
|
2011-10-12 |
2011-11-23 |
Mexichem Amanco Holding Sa |
Compositions
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
JP6267685B2
(ja)
|
2012-04-13 |
2018-01-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
集合粒子
|
JP6499077B2
(ja)
|
2012-10-25 |
2019-04-10 |
ザ ジェネラル ホスピタル コーポレイション |
アルツハイマー病と関連疾患の治療のための併用療法
|
RU2696582C2
(ru)
|
2013-03-15 |
2019-08-05 |
Перл Терапьютикс, Инк. |
Способы и системы кондиционирования дисперсных кристаллических материалов
|
GB201306984D0
(en)
|
2013-04-17 |
2013-05-29 |
Mexichem Amanco Holding Sa |
Composition
|
CN105473133A
(zh)
|
2013-04-30 |
2016-04-06 |
欧缇托匹克公司 |
干粉制剂及使用方法
|
KR101543507B1
(ko)
|
2013-05-15 |
2015-08-11 |
씨제이헬스케어 주식회사 |
연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
US9861608B2
(en)
*
|
2013-05-23 |
2018-01-09 |
Aztherapies, Inc |
Methods for delivering cromolyn
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
JP2016534063A
(ja)
*
|
2013-10-22 |
2016-11-04 |
ザ ジェネラル ホスピタル コーポレイション |
クロモリン誘導体ならびに関連するイメージングおよび治療方法
|
SI3104853T1
(sl)
|
2014-02-10 |
2020-03-31 |
Respivant Sciences Gmbh |
Zdravljenje s stabilizatorji mastocitov za sistemske motnje
|
US20150224078A1
(en)
|
2014-02-10 |
2015-08-13 |
Patara Pharma, LLC |
Methods for the Treatment of Lung Diseases with Mast Cell Stabilizers
|
CA2977083A1
(en)
|
2014-02-20 |
2015-08-27 |
Kambiz Yadidi |
Dry powder formulations for inhalation
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
AU2015296142A1
(en)
|
2014-07-31 |
2017-02-23 |
Otitopic Inc. |
Dry powder formulations for inhalation
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
MX2017005692A
(es)
|
2014-10-31 |
2017-08-07 |
Glaxosmithkline Ip Dev Ltd |
Formulacion en polvo.
|
JP6395216B2
(ja)
*
|
2014-11-13 |
2018-09-26 |
国立大学法人大阪大学 |
液体に含まれる超微細バブルの測定方法及びその測定装置
|
WO2016118625A1
(en)
|
2015-01-20 |
2016-07-28 |
Incarda Therapeutics, Inc. |
Unit aerosol doses for anticoagulation
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
US10864190B2
(en)
|
2015-04-22 |
2020-12-15 |
CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
KR20240042548A
(ko)
|
2015-06-03 |
2024-04-02 |
인타르시아 세라퓨틱스 인코포레이티드 |
임플란트 배치 및 제거 시스템들
|
US10238625B2
(en)
|
2015-08-07 |
2019-03-26 |
Respivant Sciences Gmbh |
Methods for the treatment of mast cell related disorders with mast cell stabilizers
|
WO2017027402A1
(en)
|
2015-08-07 |
2017-02-16 |
Patara Pharma, LLC |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
BR112018011266B1
(pt)
|
2015-12-04 |
2023-11-21 |
Mexichem Fluor S.A. De C.V. |
Composição farmacêutica, recipiente vedado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica
|
WO2017097986A1
(en)
|
2015-12-09 |
2017-06-15 |
Medizinische Universität Wien |
Monomaleimide-functionalized platinum compounds for cancer therapy
|
JP2019508383A
(ja)
|
2016-01-15 |
2019-03-28 |
ウニベルジテート ハンブルグUniversitaet Hamburg |
O−ラムノシル残基を有するフラボノイド型化合物
|
MX2018009248A
(es)
|
2016-02-01 |
2019-01-21 |
Incarda Therapeutics Inc |
Combinacion de monitoreo electronico con terapia farmacologica inhalada para manejar arritmias cardiacas incluyendo fibrilacion auricular.
|
CA3013988A1
(en)
|
2016-02-15 |
2017-08-24 |
Cemm-Forschungszentrum Fur Molekulare Medizin Gmbh |
Taf1 inhibitors for the therapy of cancer
|
AU2017241776A1
(en)
|
2016-03-29 |
2018-10-11 |
Janssen Biotech, Inc. |
Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
|
GB2555264A
(en)
|
2016-04-15 |
2018-04-25 |
Univ Oxford Innovation Ltd |
Adenosine receptor modulators for the treatment of circadian rhythm disorders
|
MA53353A
(fr)
|
2016-05-16 |
2021-06-09 |
Intarcia Therapeutics Inc |
Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
EP3484927A1
(en)
|
2016-07-15 |
2019-05-22 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (cars) specific for muc1 and methods for their use
|
US20190177421A1
(en)
|
2016-07-15 |
2019-06-13 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors and methods for use
|
CA3035528A1
(en)
|
2016-08-31 |
2018-03-08 |
Respivant Sciences Gmbh |
Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
|
CN109922800B
(zh)
|
2016-08-31 |
2023-06-13 |
通用医疗公司 |
与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
|
JP6781829B2
(ja)
|
2016-09-19 |
2020-11-04 |
メキシケム フロー エセ・ア・デ・セ・ヴェ |
医薬組成物
|
AU2017328910B2
(en)
|
2016-09-19 |
2020-04-09 |
Mexichem Fluor S.A. De C.V. |
Pharmaceutical composition
|
JP6781830B2
(ja)
|
2016-09-19 |
2020-11-04 |
メキシケム フロー エセ・ア・デ・セ・ヴェ |
医薬組成物
|
CN113069417A
(zh)
|
2016-09-19 |
2021-07-06 |
墨西哥氟石股份公司 |
药物组合物
|
MX2019003703A
(es)
|
2016-09-30 |
2020-08-13 |
Janssen Biotech Inc |
Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
|
EP3522983A4
(en)
|
2016-10-07 |
2020-06-03 |
Respivant Sciences GmbH |
CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
|
AU2017359288A1
(en)
|
2016-11-14 |
2019-05-30 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer
|
AU2017362222A1
(en)
|
2016-11-16 |
2019-05-30 |
Janssen Biotech, Inc. |
Method of treating psoriasis with anti-IL-23 specific antibody
|
EP3565580B1
(en)
|
2017-01-03 |
2024-03-06 |
i2o Therapeutics, Inc. |
Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
|
CN110869018A
(zh)
|
2017-05-10 |
2020-03-06 |
英凯达治疗公司 |
通过肺部施用治疗心脏病况的单位剂量、气雾剂、试剂盒和方法
|
JP7210476B2
(ja)
|
2017-05-22 |
2023-01-23 |
インスメッド インコーポレイテッド |
リポ‐グリコペプチド可切断性誘導体及びその使用
|
AU2017423862A1
(en)
|
2017-07-20 |
2020-02-06 |
Aztherapies, Inc. |
Powdered formulations of cromolyn sodium and ibuprofen
|
JP2020532987A
(ja)
|
2017-09-08 |
2020-11-19 |
ポセイダ セラピューティクス,インコーポレイティド |
キメラリガンド受容体(clr)介在性の条件遺伝子発現のための組成物および方法
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
US11744967B2
(en)
|
2017-09-26 |
2023-09-05 |
Shin Nippon Biomedical Laboratories, Ltd. |
Intranasal delivery devices
|
WO2019110139A1
(en)
|
2017-12-05 |
2019-06-13 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
AU2018393110B2
(en)
|
2017-12-20 |
2023-04-27 |
Poseida Therapeutics, Inc. |
VCAR compositions and methods for use
|
JP2021515770A
(ja)
|
2018-03-05 |
2021-06-24 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il−23特異的抗体を用いたクローン病の治療方法
|
SG11202008659TA
(en)
|
2018-03-07 |
2020-10-29 |
Poseida Therapeutics Inc |
Cartyrin compositions and methods for use
|
US10744087B2
(en)
|
2018-03-22 |
2020-08-18 |
Incarda Therapeutics, Inc. |
Method to slow ventricular rate
|
US20210163406A1
(en)
|
2018-04-06 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
|
CA3096146A1
(en)
|
2018-04-06 |
2019-10-10 |
Zilentin AG |
Bumetanide derivatives for the therapy of hyperhidrosis
|
US20190345245A1
(en)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
US10414721B1
(en)
|
2018-06-04 |
2019-09-17 |
University Of Bern |
Inhibitor of endocannabinoid cellular reuptake
|
AU2019299347A1
(en)
|
2018-07-02 |
2021-01-21 |
Aztherapies, Inc. |
Powdered formulations of cromolyn sodium and alpha-lactose
|
WO2020016838A2
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained response predictors after treatment with anti-il23 specific antibody
|
DK3883606T5
(da)
|
2018-09-24 |
2024-01-02 |
Janssen Biotech Inc |
Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof
|
WO2020104943A2
(en)
|
2018-11-20 |
2020-05-28 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-il-23 specific antibody
|
CA3122354A1
(en)
|
2018-12-17 |
2020-06-25 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
US20200197517A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
|
BR112021013156A2
(pt)
|
2019-01-03 |
2021-09-14 |
Aqua Yield Operations LLC |
Dendrímeros de pamam para entrega de fertilizante
|
JP2022525145A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体組成物を生成するための製造方法
|
KR20210141583A
(ko)
|
2019-03-18 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-il-12/il-23 항체를 사용한 소아 대상의 건선 치료 방법
|
US11932585B2
(en)
*
|
2019-04-12 |
2024-03-19 |
Aqua Yield Operations LLC |
Blended nanoparticle fertilizer delivery
|
CN110051868A
(zh)
*
|
2019-04-15 |
2019-07-26 |
宝盈联华(厦门)生物科技有限公司 |
一种带有硅碳岩、礌石粉的橱柜灭菌器
|
JP7404671B2
(ja)
*
|
2019-06-25 |
2023-12-26 |
株式会社リコー |
多孔質微粒子及びその製造方法、並びに医薬組成物
|
US11020384B2
(en)
|
2019-08-01 |
2021-06-01 |
Incarda Therapeutics, Inc. |
Antiarrhythmic formulation
|
JP7395723B2
(ja)
|
2019-10-02 |
2023-12-11 |
トルレモ・セラピューティクス・アクチェンゲゼルシャフト |
複素環式誘導体、医薬組成物および癌の処置または寛解におけるそれらの使用
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
IL292153A
(en)
|
2019-10-16 |
2022-06-01 |
Cemm Forschungszentrum Fur Molekulare Medizin Gmbh |
Oxazole and thiazole choline ubiquitin ligase ring compounds and uses thereof
|
IL297025A
(en)
|
2020-04-14 |
2022-12-01 |
Poseida Therapeutics Inc |
Preparations and methods for use in cancer treatment
|
EP4138884A1
(en)
|
2020-04-20 |
2023-03-01 |
Sorrento Therapeutics, Inc. |
Pulmonary administration of ace2 polypeptides
|
WO2021214587A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating viral infections
|
WO2021214588A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating coronavirus infections
|
BR112022026045A2
(pt)
|
2020-06-25 |
2023-01-17 |
Tolremo Therapeutics Ag |
Derivados heterocíclicos, composições farmacêutucas e seu uso no tratamento, melhora ou prevenção de doença fibrótica
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
CN111700883B
(zh)
*
|
2020-07-23 |
2021-04-06 |
深圳大佛药业股份有限公司 |
一种硫酸沙丁胺醇缓释型吸入制剂及其生产工艺
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
WO2022049382A1
(en)
|
2020-09-04 |
2022-03-10 |
Mexichem Fluor S.A. De C.V. |
Pharmaceutical composition
|
AU2021359129A1
(en)
|
2020-10-16 |
2023-06-01 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
CN112495316B
(zh)
*
|
2020-10-20 |
2021-11-19 |
大连理工大学 |
一种基于亚稳态乳液制备微纳米凝胶微球的方法
|
CN116546980A
(zh)
*
|
2020-12-11 |
2023-08-04 |
江苏恒瑞医药股份有限公司 |
用于肺部递送的药物组合物
|
EP4305062A1
(en)
|
2021-03-12 |
2024-01-17 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
IL305802A
(en)
|
2021-03-12 |
2023-11-01 |
Janssen Biotech Inc |
A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
|
EP4304582A1
(en)
|
2021-03-12 |
2024-01-17 |
Alvarius Pharmaceuticals Ltd. |
Compositions and methods for treating addictions comprising 5-meo-dmt
|
CN117355512A
(zh)
|
2021-04-07 |
2024-01-05 |
托雷莫治疗股份公司 |
杂环衍生物、药物组合物及其在治疗或改善癌症中的用途
|
AU2022306973A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
WO2023084488A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2023187707A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
WO2023203172A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|